Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer Clinical Trial
Official title:
A Prospective, One-arm Open Clinical Trial of Apatinib Combined With Albumin Paclitaxel and Carboplatin as a Neoadjuvant Therapy for the Safety and Efficacy of Triple-negative Breast Cancer
This study was a prospective, one-arm open phase II clinical trial. A systematic review of the pCR of apatinib in combination with the albumin paclitaxel and carboplatin regimens for the neoadjuvant therapy of triple-negative breast cancer, as well as the safety of treatment, at the same time, relevant exploratory biomarker research is conducted.
Neoadjuvant program: apatinib 250mg oral d1-21; albumin paclitaxel 260mg/m2 intravenous drip
d1; carboplatin AUC=5-6 intravenous drip d1; 21 days for 1 cycle. The treatment regimen was
used for a total of 6 cycles, or to PD, or the toxicity was not tolerated. If there is still
no PD after 6 cycles, the surgical approach is based on the tumor condition and the patient's
wishes. If the condition progresses to terminate the treatment regimen, the patient may
receive subsequent local or systemic treatment. The follow-up period was followed up to
assess safety and effectiveness.
MAIN OBJECTIVE: To systematically evaluate the pCR rate of apatinib combined with albumin
paclitaxel and carboplatin regimen for neoadjuvant therapy of triple-negative breast cancer
Secondary objective: To evaluate the safety of apatinib combined with albumin paclitaxel and
carboplatin in neoadjuvant therapy for triple-negative breast cancer, an exploratory
biomarker study
;